MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 317370 | Name: Carbidopa free base
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Carbidopa is a drug given to people with Parkinson's disease in order to inhibit peripheral metabolism of levodopa. This property is significant in that it allows a greater proportion of peripheral levodopa to cross the blood–brain barrier for central nervous system effect.

Chemical Structure

Carbidopa free base
Carbidopa free base
CAS#28860-95-9 (anhydrous)

Theoretical Analysis

MedKoo Cat#: 317370

Name: Carbidopa free base

CAS#: 28860-95-9 (anhydrous)

Chemical Formula: C10H14N2O4

Exact Mass: 226.0954

Molecular Weight: 226.23

Elemental Analysis: C, 53.09; H, 6.24; N, 12.38; O, 28.29

Price and Availability

Size Price Availability Quantity
1g USD 250.00 2 Weeks
2g USD 350.00 2 Weeks
5g USD 650.00 2 Weeks
10g USD 1,050.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
38821-49-7 (hydrate) 28860-95-9 (anhydrous) 65132-60-7 (HCl)
Synonym
MK485, MK 485, MK-485, Carbidopa, Lodosyn
IUPAC/Chemical Name
(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid
InChi Key
TZFNLOMSOLWIDK-JTQLQIEISA-N
InChi Code
InChI=1S/C10H14N2O4/c1-10(12-11,9(15)16)5-6-2-3-7(13)8(14)4-6/h2-4,12-14H,5,11H2,1H3,(H,15,16)/t10-/m0/s1
SMILES Code
O=C(O)[C@@](C)(NN)CC1=CC=C(O)C(O)=C1
Appearance
Solid powder
Purity
>97% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 226.23 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Liao X, Wu N, Liu D, Shuai B, Li S, Li K. Levodopa/carbidopa/entacapone for the treatment of early Parkinson's disease: a meta-analysis. Neurol Sci. 2020 Aug;41(8):2045-2054. doi: 10.1007/s10072-020-04303-x. Epub 2020 Mar 11. PMID: 32162166. 2: Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, Fernandez HH, Vanagunas A, Othman AA, Widnell KL, Robieson WZ, Pritchett Y, Chatamra K, Benesh J, Lenz RA, Antonini A; LCIG Horizon Study Group. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 2014 Feb;13(2):141-9. doi: 10.1016/S1474-4422(13)70293-X. Epub 2013 Dec 20. Erratum in: Lancet Neurol. 2014 Mar;13(3):240. PMID: 24361112; PMCID: PMC4643396. 3: Seeberger LC, Hauser RA. Carbidopa levodopa enteral suspension. Expert Opin Pharmacother. 2015;16(18):2807-17. doi: 10.1517/14656566.2015.1111336. Epub 2015 Nov 23. Erratum in: Expert Opin Pharmacother. 2016;17(5):751. PMID: 26595228. 4: Hoy SM. Levodopa/Carbidopa Enteral Suspension: A Review in Advanced Parkinson's Disease. Drugs. 2019 Oct;79(15):1709-1718. doi: 10.1007/s40265-019-01201-1. PMID: 31549300. 5: Greig SL, McKeage K. Carbidopa/Levodopa ER Capsules (Rytary(®), Numient™): A Review in Parkinson's Disease. CNS Drugs. 2016 Jan;30(1):79-90. doi: 10.1007/s40263-015-0306-3. PMID: 26692288. 6: Thakkar S, Fung VSC, Merola A, Rollins M, Soileau MJ, Kovács N. 24-Hour Levodopa-Carbidopa Intestinal Gel: Clinical Experience and Practical Recommendations. CNS Drugs. 2021 Feb;35(2):137-149. doi: 10.1007/s40263-020-00782-w. Epub 2021 Feb 13. PMID: 33582982; PMCID: PMC7907013. 7: Cansino-Torres MA, Sandoval-Rodríguez V, Sáenz-Farret M, Zúñiga-Ramírez C. Allergy to Carbidopa. Clin Neuropharmacol. 2018 Mar/Apr;41(2):75-79. doi: 10.1097/WNF.0000000000000270. PMID: 29432287. 8: Chen Z, Xia X, Chen H, Huang H, An X, Sun M, Yao Q, Kim K, Zhang H, Chu M, Chen R, Bhutia YD, Ganapathy V, Kou L. Carbidopa suppresses estrogen receptor- positive breast cancer via AhR-mediated proteasomal degradation of ERα. Invest New Drugs. 2022 Dec;40(6):1216-1230. doi: 10.1007/s10637-022-01289-5. Epub 2022 Sep 7. PMID: 36070108. 9: Wirdefeldt K, Odin P, Nyholm D. Levodopa-Carbidopa Intestinal Gel in Patients with Parkinson's Disease: A Systematic Review. CNS Drugs. 2016 May;30(5):381-404. doi: 10.1007/s40263-016-0336-5. PMID: 27138916. 10: Fitzgerald DB, Drago V, Sutherland D, Heilman KM. Carbidopa/levodopa- responsive myoclonus. Mov Disord. 2007 Feb 15;22(3):392-5. doi: 10.1002/mds.21286. PMID: 17216651. 11: True AC. Letter: Carbidopa. JAMA. 1976 Jan 12;235(2):146. doi: 10.1001/jama.235.2.146c. PMID: 946018. 12: Golden EP, Park CJ, Vernino S. Symptomatic use of carbidopa in autonomic disorders. Auton Neurosci. 2021 Dec;236:102888. doi: 10.1016/j.autneu.2021.102888. Epub 2021 Sep 29. PMID: 34610497. 13: Duopa--a carbidopa/levodopa enteral suspension for Parkinson's disease. Med Lett Drugs Ther. 2015 Aug 3;57(1474):112. PMID: 26218794. 14: Entacapone/levodopa/carbidopa combination tablet: Stalevo. Drugs R D. 2003;4(5):310-1. doi: 10.2165/00126839-200304050-00006. PMID: 12952501. 15: Hauser RA. IPX066: a novel carbidopa-levodopa extended-release formulation. Expert Rev Neurother. 2012 Feb;12(2):133-40. doi: 10.1586/ern.11.195. PMID: 22288668. 16: Guttridge D. Levodopa-carbidopa. Aust Nurses J. 1980 May;9(10):28-9. PMID: 6901482. 17: Esteban-Fernandez L, Alonso-Canovas A, Rojas-Medina LM, Ballester-MartÍnez MA, Corral-Corral I, Martinez-Castrillo JC. Carbidopa-induced eosinophilic fasciitis: A review. Neurol India. 2016 Jan-Feb;64(1):157-9. doi: 10.4103/0028-3886.173656. PMID: 26755008. 18: Olanow CW, Espay AJ, Stocchi F, Ellenbogen AL, Leinonen M, Adar L, Case RJ, Orenbach SF, Yardeni T, Oren S, Poewe W; 006 study group. Continuous Subcutaneous Levodopa Delivery for Parkinson's Disease: A Randomized Study. J Parkinsons Dis. 2021;11(1):177-186. doi: 10.3233/JPD-202285. PMID: 33164945; PMCID: PMC7990424. 19: Lettieri M, Scarano S, Palladino P, Minunni M. Colorimetric determination of carbidopa in anti-Parkinson drugs based on 4-hydroxy-3-methoxybenzaldazine formation by reaction with vanillin. Anal Bioanal Chem. 2022 Sep;414(23):6911-6918. doi: 10.1007/s00216-022-04256-4. Epub 2022 Aug 4. PMID: 35927364; PMCID: PMC9436860. 20: Rosebraugh M, Voight EA, Moussa EM, Jameel F, Lou X, Zhang GGZ, Mayer PT, Stolarik D, Carr RA, Enright BP, Liu W, Facheris MF, Kym PR. Foslevodopa/Foscarbidopa: A New Subcutaneous Treatment for Parkinson's Disease. Ann Neurol. 2021 Jul;90(1):52-61. doi: 10.1002/ana.26073. Epub 2021 May 4. PMID: 33772855; PMCID: PMC8251848.